Patent ID: 11925611
Assignee: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method for treating and/or preventing a neurodegenerative disease or a neurocognitive disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:, wherein each of X1 and X2 is independently halogen;
wherein R1 is selected from —OH, —SR10, and —NR11aR11b;
wherein each of R10, R11a,and R11b, when present, is independently selected from hydrogen and C1-C4 alkyl;

wherein each of R2a, R2b, R2c, and R2d is independently selected from hydrogen, halogen, —NO2, —CN, —OH, —SH, —NH2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 thioalkyl, C1-C4 aminoalkyl, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;
wherein each of R3a, R3b, R3c, and R3d is independently selected from hydrogen, halogen, —NO2, —CN, —OH, —SH, —NH2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 thioalkyl, C1-C4 aminoalkyl, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;
wherein R4 is selected from hydrogen and C1-C4 alkyl; and
wherein R5 is C1-C4 alkyl, provided that the compound is not:, or a pharmaceutically acceptable salt thereof,
wherein the subject has not been diagnosed as having had an ischemic stroke prior to the administering step, and
wherein the neurodegenerative disease is selected from Alzheimer's disease, cerebral autosomal dominant arteriopathy with sub-cortical infarcts and leukoencephalopathy (CADASIL), Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS/Lou Gehrig's disease), Multiple Sclerosis, spinal muscular atrophy, spinal and bulbar muscular atrophy, familial spastic paraparesis, Machado Joseph disease, Friedreich's ataxia, and Lewy body disease.